XBiotech (XBIT)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	183.12 mm	183.12 mm	183.12 mm	183.12 mm		183.12 mm
Cash burn (monthly)	5.97 mm	(no burn)	2.63 mm	2.99 mm		1.01 mm
Cash used (since last report)	16.83 mm	n/a	7.42 mm	8.42 mm		2.85 mm
Cash remaining	166.28 mm	n/a	175.69 mm	174.70 mm		180.27 mm
Runway (months of cash)	27.8	n/a	66.7	58.5		178.5

Beta Read what these cash burn values mean

Financial data from XBiotech earnings reports.

Institutional ownership, Q2 2024

XBIT institutional ownership history Ownership history

6.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	22	39	-43.6%
Opened positions	11	35	-68.6%
Closed positions	28	0	NEW
Increased positions	7	0	NEW
Reduced positions	3	2	+50.0%

13F shares	Current	Prev Q	Change
Total value	5.61 bn	23.32 bn	-75.9%
Total shares	1.99 mm	3.78 mm	-47.4%
Total puts	4.60 k	0.00	NEW
Total calls	5.80 k	0.00	NEW
Total put/call ratio	0.8	–	–

Largest owners	Shares	Value	Change
Bay Street Financial	844.86 k	$13.88 mm	0.0%
Millennium Management	361.66 k	$1.86 bn	NEW
STT State Street	202.84 k	$1.04 bn	+258.8%
Bridgeway Capital Management	154.18 k	$792.48 mm	+3.3%
MS Morgan Stanley	100.55 k	$516.83 mm	-13.6%
BK The Bank of New York Mellon Corporation	98.31 k	$505.33 mm	+102.9%
Empowered Funds	69.14 k	$355.36 mm	+7.6%
T. Rowe Price	23.63 k	$122.00 k	+34.2%
New York State Common Retirement Fund	21.70 k	$112.00 k	NEW
Rhumbline Advisers	20.09 k	$103.28 mm	+2568.5%

Largest transactions	Shares	Bought/sold	Change
Vanguard	0.00	-895.32 k	EXIT
Millennium Management	361.66 k	+361.66 k	NEW
BLK BlackRock	0.00	-306.62 k	EXIT
Credit Suisse	0.00	-248.27 k	EXIT
Geode Capital Management	0.00	-195.20 k	EXIT
Susquehanna International	0.00	-169.81 k	EXIT
STT State Street	202.84 k	+146.32 k	+258.8%
Connor, Clark & Lunn Investment Management	0.00	-77.41 k	EXIT
NTRS Northern Trust	0.00	-75.39 k	EXIT
Dimensional Fund Advisors	0.00	-72.47 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

XBIT insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
20 Jun 24	W Thorpe Mckenzie	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Waldin Jan-Paul	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Donald H. MacAdam	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
20 Jun 24	Peter Libby	Director Stock Option Common Stock	Grant	Acquire A	No	No	5.12	37,500	192.00 k	37,500
3 Jan 24	John Simard	Convertible Loan Agreement Common Shares or Preferred Shares	Buy	Acquire P	No	No	4.048001198208355	2,470,355	10.00 mm	3,840,736

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Press releases

From Benzinga Pro

XBiotech Pauses Rheumatology program

23 Dec 24

AUSTIN, Texas, Dec. 23, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently